STEAP1 and STEAP2: emerging prostate cancer targets – a pipeline review

STUTTGART, Germany I August 30, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-STEAP1- and/or STEAP2 immunotherapeutics in R&D: Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies.

This competitive intelligence report about STEAP1- and STEAP2-Targeted Immunotherapies provides a competitor evaluation in the field of product candidates in research and development targeting STEAP1- and/or STEAP2. This report will be prepared on demand within one working day upon order placement. The report lists STEAP1- and/or STEAP2 -targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of STEAP1- and/or STEAP2-targeted immunotherapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports, please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

The Six-Transmembrane Epithelial Antigen of the Prostate (STEAP) protein family, comprising STEAP1, STEAP2, STEAP3, and STEAP4, plays a vital role in cellular metal homeostasis. These proteins are located on the cell membrane and are characterized by six transmembrane domains. With the exception of STEAP1, the STEAP proteins function as metal oxidoreductases due to their F420H2:NADP+ oxidoreductase (FNO)-like domain. However, STEAP1 contributes to metal metabolism through its heme group and interaction with other STEAP proteins. Beyond metal metabolism, STEAP proteins are involved in critical cellular processes, including the regulation of the cell cycle, proliferation, differentiation, and apoptosis.

STEAP proteins are recognized as potential biomarkers and therapeutic targets in human cancers, particularly prostate cancer:

STEAP1 belongs to the STEAP family of metalloreductases that has been reported to promote cancer cell proliferation, invasion, and epithelial-to-mesenchymal transition. It is highly expressed in >80% of metastatic castration-resistant prostate cancer with limited expression in normal human tissue, and has been associated with poor survival. Overexpression of STEAP1 in prostate tumors, combined with low or no expression on normal tissues, makes STEAP1 an ideal potential therapeutic target.

Large-scale genomic and proteomic efforts have identified STEAP2 (also known as STAMP1) as a superior prostate antigen for therapeutic targeting. Consistent with this discovery, it has been shown that STEAP2 expression is abundant across all stages of prostate cancer and can be used as a prognostic biomarker owing to its correlation with Gleason score.

The report “Pipeline of STEAP1- and STEAP2-Targeted Immunotherapies” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/pipeline-of-steap1-and-steap2-targeted-immunotherapies/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, customized reports about target evaluation, pipeline analysis, technology assessments, drug and competitor profiles, partnering and business deal terms and any other competitive intelligence elaboration of interest.

Among La Merie Publishing’s services are the pre-scoped evaluation of customer-selected targets for drug discovery: Target Evaluation for Drug Discovery: Pre-Scoped Premium Evaluation.

SOURCE: La Merie Publishing